Financial Data and Key Metrics Changes - The company reported Q4 revenue of 215million,anincreaseof90.28, which was within guidance but 0.05belowprioryearlevels[6][14]−Cashfromoperationswas60 million, exceeding the high end of the guided range [6][19] - Full year free cash flow was 106million,representing1567 million, up 9% year-over-year, with gross margins at 54.2%, an increase of 260 basis points [15] - Precision Device segment revenue increased by 10% to 70million,butgrossmarginsdecreasedby13percentagepointsto35.478 million, up 8% year-over-year, with gross margins at 24.7%, 70 basis points higher than the previous year [17] Market Data and Key Metrics Changes - The Hearing Health market is expected to see strong growth in the first half of 2024, driven by aging populations and increased penetration of hearing aids [7] - Demand in the Precision Device segment remains stable despite high channel inventory, particularly in industrial and distribution markets [8][30] Company Strategy and Development Direction - The company is focused on transforming its business towards higher-value products and markets, aiming to drive long-term shareholder value [12][26] - The acquisition of Cornell is expected to provide synergies higher than initially anticipated, with a focus on cost controls and capacity optimization [9][44] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for growth across all business units in 2024, despite a challenging 2023 [12][64] - The company anticipates modest revenue growth in 2024, with a focus on managing costs and optimizing operations until market recovery occurs [32][63] Other Important Information - The company ended 2023 with 271millionindebtandanetleverageratioof1.3x2023EBITDA[20]−ForQ12024,revenueisexpectedtobebetween190 million and 200million,reflectinga3520 million, with expectations for a slightly higher run rate in Q1 [74][72]